Samarium oxide as a radiotracer to evaluate the in vivo biodistribution of PLGA nanoparticles
Source abstract
Abstract
Nuclear Technologies in Medicine and the Biosciences Initiative (NTeMBI), a national technology platform developed and managed by the South African Nuclear Energy Corporation (Necsa) and funded by the Department of Science and Technology
The source flagged this abstract for review. Check formulas and completeness against the original publication.
Source: openaire · Quality: needs review · Source record ↗
Source flags: short_text
Source flags: short_text
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Bone Tissue Engineering Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (16)
Show source-provided references
1. Ali MM, Yoo B, Pagel MD (2009) Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI. Mol Pharm 6(5):1409–141610.1021/mp900040u ↗
2. Caruthers SD, Wickline SA, Lanza GM (2007) Nanotechnological applications in medicine. Curr Opin Biotechnol 18(1):26–3010.1016/j.copbio.2007.01.006 ↗
3. Koo OM, Rubinstein I, Onyuksel H (2005) Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomedicine 1:193–21210.1016/j.nano.2005.06.004 ↗
4. Lambrecht A, Ubrich N, Perez MH, Lehr CM, Hoffman J, Maincent P (1999) Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification. Int J Pharm 184(1):97–10510.1016/S0378-5173(99)00107-6 ↗
5. Mohammed AK, Reineke JJ (2013) Quantitative detection of PLGA nanoparticles degradation in tissues following intravenous administration. Mol Pharm 10(6):2183–218910.1021/mp300559v ↗
6. Orive G, Hernandez RM, Gascon AR, Dominguez-Gil A, Pedra ZJ (2003) Drug delivery in biotechnology: present and future. Curr Opin Biotechnol 14:659–66410.1016/j.copbio.2003.10.007 ↗
7. Parhi R, Suresh P (2012) Preparation and characterisation of solid lipid nanoparticles-a review. Curr Drug Discov Technol 9:2–1610.2174/157016312799304552 ↗
8. Parveen S, Misra R, Sahoo SK (2012) Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 8:147–16610.1016/j.nano.2011.05.016 ↗
9. Perkins AC, Frier M (2004) Radionuclide imaging in drug development. Curr Pharm Des 10:2907–292110.2174/1381612043383476 ↗
10. Semete B, Booysen L, Lemmer Y, Kalombo L, Venter J, Katata L, Verschoor J, Swai H (2010) In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems, Nanomedicine 6:662–67110.1016/j.nano.2010.02.002 ↗
11. Smola M, Vandamme T, Sokolowski A (2008) Nanocarriers aspulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases. Int J Nanomed 3(1):1–1910.2217/17435889.3.1.1 ↗
12. Venter L, Jansen D, Wagener J, Fourie PB, Zeevaart JR (2012) Characterization of radiolabelled dry powder leucine, a constituent of inhalable capreomycin. Drug Deliv Lett 2:155–161
13. Vergoni AV, Tosi G, Tacchi R, VAndelli MA, Bertolini A, Costantino L (2009) Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomed Nanotechnol Biol Med 5:369–37710.1016/j.nano.2009.02.005 ↗
14. Yeong CH, Abdullah BJJ, Ng KH, Chung LY, Goh KL, Sarji SA, Perkins AC (2011a) Neutron activated 153Sm-ion-exchange resin as a tracer for gastrointestinal Scintigraphy. Nucl Med Commun 32(12):1256–126010.1097/MNM.0b013e32834b3ac8 ↗
15. Yeong CH, Blackshaw PE, Ng KH, Abdullah BJJ, Blaauw M, Dansereau RJ, Perkins AC (2011b) Reproductivity of neutron activated Sm-153 oral dose formulations intended for human administration. Appl Radiat Isot 69(9):1181–118410.1016/j.apradiso.2011.04.017 ↗
16. Yeong CH, Abdullah BJJ, Ng KH, Chung LY, Goh KL, Sarji SA, Perkins AC (2012) Production and first use of 153SmCl3-ion exchange resin capsule formulation for assessing gastrointestinal motility. Appl Radiat Isot 70:450–45510.1016/j.apradiso.2011.11.056 ↗